HCC
Conditions
Interventions
A Group:Western medicine treatment: Lenvatinib 8 mg once daily (for body weight <60 kg) or 12 mg once daily (for body weight =60 kg), Tislelizumab 200 mg every 3 weeks, local treatment (TACE or HAIC).
C Group:atilizumab in combination with bevacizumab anti (T+A) therapy, localized therapy (TACE or HAIC). Traditional Chinese medicine treatment: Ye Xiazhu Wuzhong Tang plus subtraction
B Group:Western medicine treatment: Lenvatinib 8mg qd (body weight less than 60kg) or 12mg qd (body weight greater than or equal to 60mg), Tirilizumab 200mg Q3W, localized therapy (TACE or HAIC). (TAC
D Group:atilizumab in combination with bevacizumab anti (T+A) therapy, localized therapy (TACE or HAIC). Herbal therapy: no
Sponsors
Shenzhen Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1) Hepatocellular carcinoma associated with HBV infection confirmed clinically and pathologically; 2) CNLC staging: Stage IIb Stage IIIa Stage IIIb and clinically proven to be not directly resectable by surgery; 3) Child-pugh: Grade A; 4) Not receiving systemic treatment; 5) Male or female aged greater than or equal to18 years and less than or equal to 65 years who have signed an informed consent form; 6) ECOG score of 0 or 1 and expected survival of more than 3 months.
Exclusion criteria
Exclusion criteria: 1 Combined with other hepatophilic viruses and HIV infection; 2 Persons with severe cardiac renal pulmonary hematologic metabolic and gastrointestinal disorders; 3 Pregnant or lactating women. 4 Allergic or allergic to multiple drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate;Overall survival;Progression-free survival;Time to disease progression;Success rate of conversion surgery;Quality of life;Safety and tolerability; | — |
Countries
China
Contacts
Public Contactliujiulin
Shenzhen Hospital of Traditional Chinese Medicine
Outcome results
None listed